ReviewAdvanced drug delivery reviews2014
Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care.
Review in Advanced drug delivery reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- A Benchtop Automated Sputum-to-Genotype System Using a Lab-on-a-Film Assembly for Detection of Multidrug-ResistantAnalytical chemistry · 2020Article
- Point of care testing for infectious diseases.Clinica chimica acta; international journal of clinical chemistry · 2019Review
- Emerging Microtechnologies and Automated Systems for Rapid Bacterial Identification and Antibiotic Susceptibility Testing.SLAS technology · 2017Article
- A mutation-resistant deoxyribozyme OR gate for highly selective detection of viral nucleic acids.Chemical communications (Cambridge, England) · 2017Article
- Accurate and effective multidrug-resistant Mycobacterium tuberculosis detection method using gap-filling ligation coupled with high-resolution capillary electrophoresis-based single strand conformation polymorphism.Scientific reports · 2017Article
- Photonic crystals: emerging biosensors and their promise for point-of-care applications.Chemical Society reviews · 2017Review
- Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country.PLoS neglected tropical diseases · 2016Article
- Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis using TaqMan Allelic Discrimination.Osong public health and research perspectives · 2016Article
- Engineering long shelf life multi-layer biologically active surfaces on microfluidic devices for point of care applications.Scientific reports · 2016Article
- Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings.Expert review of molecular diagnostics · 2016Review
- Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Portable microfluidic integrated plasmonic platform for pathogen detection.Scientific reports · 2015Article
- Paper and flexible substrates as materials for biosensing platforms to detect multiple biotargets.Scientific reports · 2015Article
- Nanomechanical motion ofApplied physics letters · 2014Article
- Advances in microfluidics in combating infectious diseases.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
Infectious diseases are the leading cause of death worldwide. Among them, tuberculosis (TB) remains a major threat to public health, exacerbated by the emergence of multiple drug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (Mtb). MDR-Mtb strains are resistant to first-line anti-TB drugs such as isoniazid and rifampicin; whereas XDR-Mtb strains are resistant to additional drugs including at least to any fluoroquinolone and one of the second-line anti-TB injectable drugs such as kanamycin, capreomycin, or amikacin. Clinically, these strains have significantly impacted the management of TB in high-incidence developing countries, where systemic surveillance of TB drug resistance is lacking. For effective management of TB on-site, early detection of drug resistance is critical to initiate treatment, to reduce mortality, and to thwart drug-resistant TB transmission. In this review, we discuss the diagnostic challenges to detect drug-resistant TB at the point-of-care (POC). Moreover, we present the latest advances in nano/microscale technologies that can potentially detect TB drug resistance to improve on-site patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.